[G24-23] Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – Second Addendum to Project A24-46

Last updated 17.10.2024

Project no.:
G24-23

Commission:
Commission awarded on 10.09.2024 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Health Economics

Topic:
Cancer

Note:

If, in the course of the discussions on a commission of the G-BA, a need for further revision arises, IQWiG presents its report in the form of an addendum. The G-BA decides on the number of patients in the SHI target population.

DOI:

https://doi.org/10.60584/G24-23

Federal Joint Committee (G-BA)

2024-10-17 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form